Abstract
Hyperhomocysteinemia is increasingly recognized as an independent risk factor for several cerebral, vascular, ocular, and agerelated disorders. Whether it is a cause or a consequence or a mere marker necessitates further clarification. This review focuses on the pathophysiological aspects of homocysteines involvement in neurodegenerative and neuropsychiatric disorders and complications. The pharmacological agents (antiepileptic drugs, L-DOPA) augment the homocysteine levels, thus, raising concern for physicians. The mechanisms underlying the enhanced homocysteine levels and its related pathophysiological cascades remain poorly understood, inspite of numerous epidemiological and research studies that have been carried out in recent years. This article will review the current understanding of these underlying mechanisms and the research being carried with homocysteine as a core molecule.
Keywords: Homocysteine, homocysteine thiolactone, hyperhomocysteinemia, diagnostic marker, prognostic marker, predictive marker, L-DOPA, HCY, Folic acid, Pyridoxine, Cobalamin, Trimethylglycine, Choline, Melatonin, MK-801
CNS & Neurological Disorders - Drug Targets
Title: Homocysteine in Neurological Disease: A Marker or a Cause?
Volume: 10 Issue: 3
Author(s): Suruchi Khanna, Puneet Kapoor, K. K. Pillai and Divya Vohora
Affiliation:
Keywords: Homocysteine, homocysteine thiolactone, hyperhomocysteinemia, diagnostic marker, prognostic marker, predictive marker, L-DOPA, HCY, Folic acid, Pyridoxine, Cobalamin, Trimethylglycine, Choline, Melatonin, MK-801
Abstract: Hyperhomocysteinemia is increasingly recognized as an independent risk factor for several cerebral, vascular, ocular, and agerelated disorders. Whether it is a cause or a consequence or a mere marker necessitates further clarification. This review focuses on the pathophysiological aspects of homocysteines involvement in neurodegenerative and neuropsychiatric disorders and complications. The pharmacological agents (antiepileptic drugs, L-DOPA) augment the homocysteine levels, thus, raising concern for physicians. The mechanisms underlying the enhanced homocysteine levels and its related pathophysiological cascades remain poorly understood, inspite of numerous epidemiological and research studies that have been carried out in recent years. This article will review the current understanding of these underlying mechanisms and the research being carried with homocysteine as a core molecule.
Export Options
About this article
Cite this article as:
Khanna Suruchi, Kapoor Puneet, K. Pillai K. and Vohora Divya, Homocysteine in Neurological Disease: A Marker or a Cause?, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653797
DOI https://dx.doi.org/10.2174/187152711794653797 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Near Infrared Optical Technologies to Illuminate the Status of the Neonatal Brain
Current Pediatric Reviews A Copeptin as a Predictor Marker for Insulin Resistance Among Women with Polycystic Ovary Syndrome
Current Women`s Health Reviews Pharmacological Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design Does a Physically Active Lifestyle Attenuate Decline in All Cognitive Functions in Old Age?
Current Aging Science Achieving Better Blood Pressure Control in High-Risk Patients with Type 2 Diabetes Using Combination Antihypertensive Therapy
Vascular Disease Prevention (Discontinued) Artificial Blood: A Futuristic Dimension of Modern Day Transfusion Sciences
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot Topic: Experimental Models for the Study of Drugs Used to Prevent and Treat Vascular Diseases (Executive Editors: C.S. Thompson, D.P. Mikhailidis and K.I. Paraskevas)]
Current Pharmaceutical Design Circulating Endothelial Progenitor Cells Biology and Regenerative Medicine in Pulmonary Vascular Diseases
Current Pharmaceutical Biotechnology GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic Targeting
Current Molecular Pharmacology Serum Arylsulfatase and Acid Phosphatase Activity in Patients with Metabolic Syndrome as a Result of Oxidative Damage to Lysosomes
Protein & Peptide Letters Anti-Platelet Therapy and Aspirin Resistance – Clinically and Chemically Relevant?
Current Medicinal Chemistry Effects of Carotenoids on Health: Are All the Same? Results from Clinical Trials
Current Pharmaceutical Design Disorders of Mineral Metabolism in the Newborn
Current Pediatric Reviews Pediatrics for Disability: A Comprehensive Approach to Children with Syndromic Psychomotor Delay
Current Pediatric Reviews Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design Periodontitis and Redox Status: A Review
Current Pharmaceutical Design Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Endothelial Dysfunction in Hyperglycemia as a Trigger of Atherosclerosis
Current Diabetes Reviews